The University of Chicago received a $1,612,104 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Senescent Tumor Cell-Loaded Dendritic Cell Vaccines for Breast Cancer." The award period runs from February 1, 2025 to January 31, 2028. This grant supports the university's cutting-edge research into developing novel cancer immunotherapy approaches, specifically exploring the use of senescent tumor cell-loaded dendritic cell vaccines for the treatment of breast cancer. As a leading research institution, the University of Chicago leverages its world-class faculty, state-of-the-art facilities, and interdisciplinary expertise to drive innovation in medical research areas critical to national priorities, including addressing challenging health conditions affecting military personnel and the general public.
Generated 3/4/25, 7:55 AM